Malabre Richard C 4

What Happened

• Richard C. Malabre, Akebia Therapeutics' Senior Vice President and Chief Accounting Officer, was awarded two equity grants on January 30, 2026: 79,000 restricted stock units (RSUs) and 119,000 derivative awards (stock options/other equity derivative). Both grants show an acquisition price of $0.00 (typical for awards/grants — no cash paid at grant).
• The filing (Form 4) was submitted on February 3, 2026 and reports the grants; the awards’ future value depends on Akebia’s future stock price and required vesting service.

Key Details

• Transaction date: 2026-01-30; Filing date: 2026-02-03 (filed within required two business days).
• Grants: 79,000 RSUs (F1) and 119,000 derivative awards (listed as "Derivative") — acquisition price reported $0.00 for each.
• Vesting/terms (per filing footnotes):
  • F1 (RSUs): Granted under the 2023 Stock Incentive Plan; vest 1/3 on each of the first, second and third anniversaries of the grant, subject to continued service.
  • F3 (options/derivative): Granted under the 2023 Stock Incentive Plan; vest over four years — 25% on the first anniversary, then remaining 75% in equal quarterly installments, subject to continued service.
• Footnote F2 notes prior ESPP purchases (1,500 shares on 6/30/2025 and 1,500 shares on 12/31/2025) included in holdings disclosure.
• Shares owned after the transaction are not specified in the provided filing excerpt.

Context

• These are standard equity compensation awards (RSUs and options) to an executive and do not reflect an open-market purchase or sale. Grants are common for employee compensation and align retention via time-based vesting.
• Because the grants were issued at $0.00, no cash changed hands at grant; any benefit to the insider materializes only if/when awards vest and (for options) are exercised at favorable market prices.